160 related articles for article (PubMed ID: 34214131)
21. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
Lassen P; Lacas B; Pignon JP; Trotti A; Zackrisson B; Zhang Q; Overgaard J; Blanchard P;
Radiother Oncol; 2018 Jan; 126(1):107-115. PubMed ID: 29100700
[TBL] [Abstract][Full Text] [Related]
22. The interaction of smoking habit, SLPI and AnxA2 in HPV associated head and neck and other cancers.
Hoffmann M; Quabius ES; Fabian A; Laudien M; Ambrosch P
Cancer Treat Res Commun; 2021; 26():100299. PubMed ID: 33387869
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of human papillomavirus detection in oral rinse as a biomarker of oropharyngeal cancer.
Yoshida H; Murono S; Ueno T; Nakanishi Y; Tsuji A; Hatano M; Endo K; Kondo S; Sugimoto H; Wakisaka N; Yoshizaki T
Acta Otolaryngol; 2017 Jul; 137(7):773-777. PubMed ID: 28093931
[TBL] [Abstract][Full Text] [Related]
24. Oral health and human papillomavirus-associated head and neck squamous cell carcinoma.
Mazul AL; Taylor JM; Divaris K; Weissler MC; Brennan P; Anantharaman D; Abedi-Ardekani B; Olshan AF; Zevallos JP
Cancer; 2017 Jan; 123(1):71-80. PubMed ID: 27571516
[TBL] [Abstract][Full Text] [Related]
25. Proteomic Alterations in Salivary Exosomes Derived from Human Papillomavirus-Driven Oropharyngeal Cancer.
Tang KD; Wan Y; Zhang X; Bozyk N; Vasani S; Kenny L; Punyadeera C
Mol Diagn Ther; 2021 Jul; 25(4):505-515. PubMed ID: 34080172
[TBL] [Abstract][Full Text] [Related]
26. HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status.
Anderson KS; Dahlstrom KR; Cheng JN; Alam R; Li G; Wei Q; Gross ND; Chowell D; Posner M; Sturgis EM
Oral Oncol; 2015 Jul; 51(7):662-7. PubMed ID: 25957822
[TBL] [Abstract][Full Text] [Related]
27. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
Lin AL; Johnson DA; Stephan KT; Yeh CK
J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
[TBL] [Abstract][Full Text] [Related]
28. Quantitative proteomic analysis of oral brush biopsies identifies secretory leukocyte protease inhibitor as a promising, mechanism-based oral cancer biomarker.
Yang Y; Rhodus NL; Ondrey FG; Wuertz BR; Chen X; Zhu Y; Griffin TJ
PLoS One; 2014; 9(4):e95389. PubMed ID: 24748380
[TBL] [Abstract][Full Text] [Related]
29. Abnormal cytology in oropharyngeal brushings and in oral rinses is not associated with HPV infection: The OHMAR study.
Benevolo M; Rollo F; Giuliani M; Pichi B; Latini A; Pellini R; Vescio MF; Morrone A; Cristaudo A; Donà MG
Cancer Cytopathol; 2020 Sep; 128(9):648-655. PubMed ID: 32485093
[TBL] [Abstract][Full Text] [Related]
30. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy.
Huang SH; Perez-Ordonez B; Liu FF; Waldron J; Ringash J; Irish J; Cummings B; Siu LL; Kim J; Weinreb I; Hope A; Gullane P; Brown D; Shi W; O'Sullivan B
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):276-83. PubMed ID: 20950953
[TBL] [Abstract][Full Text] [Related]
31. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer.
Hanna GJ; Lau CJ; Mahmood U; Supplee JG; Mogili AR; Haddad RI; Jänne PA; Paweletz CP
Oral Oncol; 2019 Aug; 95():120-126. PubMed ID: 31345379
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.
Rettig EM; Wentz A; Posner MR; Gross ND; Haddad RI; Gillison ML; Fakhry C; Quon H; Sikora AG; Stott WJ; Lorch JH; Gourin CG; Guo Y; Xiao W; Miles BA; Richmon JD; Andersen PE; Misiukiewicz KJ; Chung CH; Gerber JE; Rajan SD; D'Souza G
JAMA Oncol; 2015 Oct; 1(7):907-15. PubMed ID: 26226294
[TBL] [Abstract][Full Text] [Related]
33. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
Baqui AA; Meiller TF; Falkler WA
Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568
[TBL] [Abstract][Full Text] [Related]
34. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
35. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.
Huang SH; Xu W; Waldron J; Siu L; Shen X; Tong L; Ringash J; Bayley A; Kim J; Hope A; Cho J; Giuliani M; Hansen A; Irish J; Gilbert R; Gullane P; Perez-Ordonez B; Weinreb I; Liu FF; O'Sullivan B
J Clin Oncol; 2015 Mar; 33(8):836-45. PubMed ID: 25667292
[TBL] [Abstract][Full Text] [Related]
36. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil elastase and endogenous inhibitors in Behçet's disease saliva.
Novak T; Fortune F; Bergmeier L; Khan I; Hagi-Pavli E
Clin Exp Immunol; 2020 Oct; 202(1):93-105. PubMed ID: 32580239
[TBL] [Abstract][Full Text] [Related]
38. Risk factors in oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden.
Rosenquist K
Swed Dent J Suppl; 2005; (179):1-66. PubMed ID: 16335030
[TBL] [Abstract][Full Text] [Related]
39. Quantitative Bias Analysis of misclassification in case-control studies: an example with Human Papillomavirus and Oropharyngeal Cancer.
Durán D; Al-Soneidar WA; Madathil SA; Kaufman JS; Nicolau B
Community Dent Health; 2020 Feb; 37(1):96-101. PubMed ID: 32031348
[TBL] [Abstract][Full Text] [Related]
40. Cervical Local Immune Response for High-Risk Human Papillomavirus Infection: Involvement With Cervical Mucus SLPI Proteins.
Sahin E; Madendag Y; Sahin ME; Madendag IC; Acmaz G; Karakukcu C; Karaman H; Muderris II
Cancer Control; 2018; 25(1):1073274818798598. PubMed ID: 30180755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
